Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Fourth Quarter and Fiscal Year 2012 Financial Results:
Total operating expenses for the fourth quarter ended
Total operating expenses for the fiscal year ended
Anthera ended the fourth quarter of 2012 with approximately
The Company intends to host a conference call during the second quarter of 2013 to provide an update on the Company's clinical development plan.
Recent Management Update:
"I am excited to welcome Sandy to the Anthera Board of Directors," said Dr.
About
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the
CONTACT:
| |||||||||
A | |||||||||
STATEMENT OF OPERATIONS | |||||||||
(unaudited) | |||||||||
(in thousands except share and per share data) | |||||||||
Three Months Ended |
Twelve Months Ended Dec 31, | ||||||||
2012 |
2011 |
2012 |
2011 | ||||||
OPERATING EXPENSE: |
|||||||||
Research and development |
$ 7,089 |
$ 26,832 |
$ 49,219 |
$ 85,281 | |||||
General and administrative |
1,000 |
1,597 |
6,715 |
7,857 | |||||
Total operating expense |
8,089 |
28,429 |
55,934 |
93,138 | |||||
LOSS FROM OPERATIONS: |
(8,089) |
(28,429) |
(55,934) |
(93,138) | |||||
OTHER (EXPENSE)/INCOME: |
|||||||||
Other (expense) income |
(27) |
185 |
(111) |
606 | |||||
Interest expense |
(797) |
(912) |
(3,354) |
(2,803) | |||||
Total other income (expense) |
(824) |
(727) |
(3,465) |
(2,197) | |||||
NET LOSS |
$ (8,913) |
$ (29,156) |
$ (59,399) |
$ (95,335) | |||||
Net loss per share--basic and diluted |
$ (0.11) |
$ (0.71) |
$ (1.03) |
$ (2.55) | |||||
Weighted-average number of shares used in per share calculation-- basic and diluted |
79,120,940 |
40,916,666 |
57,803,491 |
37,417,775 | |||||
| |||
A | |||
BALANCE SHEET DATA | |||
(unaudited) | |||
(in thousands except share amounts) | |||
December 31, |
December 31, | ||
Cash and cash equivalents |
$ 19,431 |
$ 65,624 | |
Short term investments |
$ 5,322 |
$ 1,746 | |
Total assets |
$ 26,445 |
$ 69,493 | |
Total current liabilities, excluding current portion of notes payable |
$ 9,421 |
$ 26,078 | |
Total notes payable |
$ 20,550 |
$ 24,331 | |
Deficit accumulated during development stage |
$ (260,378) |
$ (200,979) | |
Total shareholders' equity(deficit) |
$ (3,526) |
$ 19,084 | |
Common shares outstanding |
79,151,592 |
40,933,354 | |
SOURCE
News Provided by Acquire Media